Bethesda, MD – [BUSINESS WIRE] – Northlane Capital Partners (NCP), a prominent middle-market private equity firm, has announced a significant investment in United States Drug Testing Laboratories Inc. (USDTL), a leading forensic toxicology laboratory specializing in alcohol and substance use testing. This strategic partnership, alongside USDTL’s management and founders Veronica and Doug Lewis, marks a pivotal moment for USDTL as it enters a new phase of growth and innovation.
USDTL, headquartered in Des Plaines, Illinois, is renowned for its comprehensive suite of forensic testing services. The company provides critical services to a diverse clientele, including hospitals, health systems, court systems, and employers, both domestically and internationally. With a strong workforce of over 160 employees and serving more than 1,000 customers, USDTL has established itself as a trusted leader in the forensic toxicology field. More information about USDTL’s services can be found at https://www.usdtl.com/.
Veronica Lewis, Founder of USDTL, expressed enthusiasm about the partnership, stating, “Welcoming Northlane Capital Partners as our first institutional partner is a momentous achievement for USDTL. After three decades dedicated to building this platform, we are excited to collaborate with NCP. Their profound expertise and understanding of the lab services sector were evident throughout the due diligence process, reinforcing our confidence in their ability to support our continued growth and investment in the business.”
Justin DuFour, Partner at Northlane Capital Partners, also commented on the investment, “USDTL has been a pioneering force in specialized forensic testing for over 30 years. Northlane Capital Partners is thrilled to partner with another founder-owned company, and we are ideally positioned to facilitate the company’s ongoing expansion. We intend to leverage our extensive network and operational experience to implement strategic initiatives that will enhance USDTL’s market position and broaden its specialized testing capabilities.”
In conjunction with this investment, USDTL has appointed Albert Berger as the new Chief Executive Officer. Berger brings over two decades of leadership experience in forensic toxicology and laboratory services. His previous roles include CEO of Confirm Biosciences and CEO of Redwood Toxicology, making him exceptionally qualified to lead USDTL into its next chapter. “I am honored to join the talented team at USDTL and eager to contribute to the company’s growth trajectory in partnership with Northlane Capital Partners,” said Albert Berger.
About Northlane Capital Partners
Northlane Capital Partners, based in Bethesda, MD, focuses on investments in the healthcare and business services sectors. The firm is committed to partnering with market-leading companies and exceptional management teams to drive growth and create value. Northlane Capital Partners’ principals have a proven track record, having deployed over $1.7 billion of equity capital. For additional information about Northlane Capital Partners, please visit www.northlanecapital.com.
Key Contacts:
Justin DuFour, Partner (301) 841-1375
Chase Edmonds, Principal (240) 319-4102
Matt Orozco, Vice President (301) 941-3725
